Ruiqing Peng

722 total citations
27 papers, 503 citations indexed

About

Ruiqing Peng is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ruiqing Peng has authored 27 papers receiving a total of 503 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 12 papers in Molecular Biology and 11 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ruiqing Peng's work include Sarcoma Diagnosis and Treatment (10 papers), Vascular Tumors and Angiosarcomas (5 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Ruiqing Peng is often cited by papers focused on Sarcoma Diagnosis and Treatment (10 papers), Vascular Tumors and Angiosarcomas (5 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Ruiqing Peng collaborates with scholars based in China, United States and Hong Kong. Ruiqing Peng's co-authors include Min Liu, Haiying Wan, Haifang Li, Xin Li, Hua Tang, Ya Ding, Xing Zhang, Xiaoshi Zhang, Jingjing Zhao and Xizhi Wen and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Oncogene.

In The Last Decade

Ruiqing Peng

26 papers receiving 491 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ruiqing Peng China	12	293	183	160	99	79	27	503
Frank Tsai United States	14	185 0.6×	58 0.3×	278 1.7×	154 1.6×	97 1.2×	36	483
Kristina Goetze Germany	7	231 0.8×	240 1.3×	83 0.5×	79 0.8×	56 0.7×	9	417
Simantini Eddy United States	6	190 0.6×	161 0.9×	165 1.0×	76 0.8×	97 1.2×	8	409
Song Wei China	2	225 0.8×	162 0.9×	57 0.4×	135 1.4×	33 0.4×	2	411
Militsa Rakina Russia	8	157 0.5×	80 0.4×	156 1.0×	235 2.4×	50 0.6×	12	410
Tiziana Piazza Italy	12	150 0.5×	66 0.4×	209 1.3×	249 2.5×	56 0.7×	15	505
Sheera R. Rosenbaum United States	9	238 0.8×	67 0.4×	185 1.2×	139 1.4×	89 1.1×	13	410
Kyle M. LaPak United States	6	187 0.6×	55 0.3×	113 0.7×	55 0.6×	63 0.8×	11	353
Haley L. Peters United States	10	174 0.6×	81 0.4×	175 1.1×	112 1.1×	49 0.6×	11	381
Fernando López-Calderón Spain	8	254 0.9×	139 0.8×	93 0.6×	71 0.7×	48 0.6×	11	409

Countries citing papers authored by Ruiqing Peng

Since Specialization

Citations

This map shows the geographic impact of Ruiqing Peng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruiqing Peng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruiqing Peng more than expected).

Fields of papers citing papers by Ruiqing Peng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ruiqing Peng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruiqing Peng. The network helps show where Ruiqing Peng may publish in the future.

Co-authorship network of co-authors of Ruiqing Peng

This figure shows the co-authorship network connecting the top 25 collaborators of Ruiqing Peng. A scholar is included among the top collaborators of Ruiqing Peng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ruiqing Peng. Ruiqing Peng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhang, Peng, Jie Ma, Shining Li, et al.. (2025). The efficacy and safety of gemcitabine and docetaxel in pseudomyogenic hemangioendothelioma: a multi-center experience. BMC Cancer. 25(1). 1030–1030.

Liu, Jiayong, Tian Gao, Qiuzhong Pan, et al.. (2024). Phase IIA study of high-affinity TCR-T (TAEST16001) targeting NY-ESO-1 in soft tissue sarcoma.. Journal of Clinical Oncology. 42(16_suppl). 11548–11548. 1 indexed citations

Pan, Qiuzhong, Haomiao Li, Xianan Li, et al.. (2023). Anlotinib as a maintenance treatment for advanced soft tissue sarcoma after first-line chemotherapy (ALTER-S006): a multicentre, open-label, single-arm, phase 2 trial. EClinicalMedicine. 64. 102240–102240. 17 indexed citations

Zhu, Ming, Ruiqing Peng, Xin Liang, et al.. (2021). P4HA2-induced prolyl hydroxylation suppresses YAP1-mediated prostate cancer cell migration, invasion, and metastasis. Oncogene. 40(41). 6049–6056. 28 indexed citations

Zhao, Hu, Xiaoli Wei, Yuqing Huang, et al.. (2021). 1329P A single-arm, open-label, multi-center, phase I study of HA121-28 in patients with advanced solid tumors. Annals of Oncology. 32. S1018–S1018. 3 indexed citations

Wen, Xizhi, Dandan Li, Jingjing Zhao, et al.. (2020). Time-varying pattern of recurrence risk for localized melanoma in China. World Journal of Surgical Oncology. 18(1). 6–6. 7 indexed citations

Peng, Ruiqing, et al.. (2019). miR-214 down-regulates MKK3 and suppresses malignant phenotypes of cervical cancer cells. Gene. 724. 144146–144146. 18 indexed citations

Xiao, Wei, Yao Liang, Yi Que, et al.. (2019). Comparison of the MAID (AI) and CAV/IE regimens with the predictive value of cyclic AMP-responsive element-binding protein 3 like protein 1 (CREB3L1) in palliative chemotherapy for advanced soft-tissue sarcoma patients. Journal of Cancer. 10(15). 3517–3525. 7 indexed citations

Xiao, Wei, Yi Que, Ruiqing Peng, et al.. (2018). A favorable outcome of advanced dermatofibrosarcoma protuberans under treatment with sunitinib after imatinib failure. OncoTargets and Therapy. Volume 11. 2439–2443. 9 indexed citations

10.

Que, Yi, Yao Liang, Jingjing Zhao, et al.. (2018). Treatment-related adverse effects with pazopanib, sorafenib and sunitinib in patients with advanced soft tissue sarcoma: a pooled analysis. Cancer Management and Research. Volume 10. 2141–2150. 26 indexed citations

11.

Peng, Ruiqing, et al.. (2017). miR-214 down-regulates ARL2 and suppresses growth and invasion of cervical cancer cells. Biochemical and Biophysical Research Communications. 484(3). 623–630. 46 indexed citations

12.

Wen, Xizhi, Ya Ding, Jingjing Li, et al.. (2017). The experience of immune checkpoint inhibitors in Chinese patients with metastatic melanoma: a retrospective case series. Cancer Immunology Immunotherapy. 66(9). 1153–1162. 34 indexed citations

13.

Wen, Xizhi, Yao Wang, Ya Ding, et al.. (2016). Safety of immune checkpoint inhibitors in Chinese patients with melanoma. Melanoma Research. 26(3). 284–289. 21 indexed citations

14.

Jiang, Feng, Yi Que, Zhi-Rui Lin, et al.. (2015). The clinical significance of transforming acidic coiled-coil protein 3 expression in non-small cell lung cancer. Oncology Reports. 35(1). 436–446. 18 indexed citations

15.

Peng, Ruiqing, Haiying Wan, Haifang Li, et al.. (2012). MicroRNA-214 Suppresses Growth and Invasiveness of Cervical Cancer Cells by Targeting UDP-N-acetyl-α-d-galactosamine:Polypeptide N-Acetylgalactosaminyltransferase 7. Journal of Biological Chemistry. 287(17). 14301–14309. 149 indexed citations

16.

Zhao, Weifeng, et al.. (2011). Mechanism of Anoikis Resistance Mediated by PYK2 in H460 Lung Carcinoma Cells. Journal of Sun Yat-sen University. 32(3). 297. 1 indexed citations

17.

Peng, Ruiqing, Chunyan Li, Xing-Juan Yu, et al.. (2011). Expression and clinical significance of high mobility group box 1 in stage IIIB colon cancer. Jiefangjun yixue zazhi. 36(3). 281–286. 1 indexed citations

18.

Li, Chunyan, et al.. (2009). Expression of beclin-1, an autophagy-related protein, in stage III B colon cancer and its relationship with prognosis. Clinical Oncology and Cancer Research. 36(3). 146–149. 1 indexed citations

19.

Peng, Ruiqing, Jiang Li, Ya Ding, et al.. (2009). The paradoxical patterns of expression of indoleamine 2,3-dioxygenase in colon cancer. Journal of Translational Medicine. 7(1). 71–71. 54 indexed citations

20.

Liu, Jiyan, Xiaoshi Zhang, Ya Ding, et al.. (2005). The changes of CD4+CD25+/CD4+ proportion in spleen of tumor-bearing BALB/c mice. Journal of Translational Medicine. 3(1). 5–5. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact